GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.7139
-0.0208 (-2.83%)
Dec 19, 2025, 10:58 AM EST - Market open
GT Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
7.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Mar 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Mar 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Mar 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 27.00K | -34.00K | -55.74% |
| Dec 31, 2014 | 61.00K | -307.00K | -83.42% |
| Dec 31, 2013 | 368.00K | 26.00K | 7.60% |
| Dec 31, 2012 | 342.00K | 316.00K | 1,215.38% |
| Dec 31, 2011 | 26.00K | 15.00K | 136.36% |
| Dec 31, 2010 | 11.00K | -37.00K | -77.08% |
| Dec 31, 2009 | 48.00K | -1.10M | -95.80% |
| Dec 31, 2008 | 1.14M | -581.00K | -33.70% |
| Dec 31, 2007 | 1.72M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GTBP News
- 4 weeks ago - GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials - Accesswire
- 5 weeks ago - GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - GT Biopharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 - GlobeNewsWire
- 6 months ago - GT Biopharma Appoints New Member to its Board of Directors - GlobeNewsWire
- 7 months ago - GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals - GlobeNewsWire
- 10 months ago - GT Biopharma Announces Exercise of Warrants - GlobeNewsWire
- 1 year ago - GT Biopharma Reports Third Quarter 2024 Financial Results - GlobeNewsWire